Home > Research > Publications & Outputs > Nesfatin-1, a unique regulatory neuropeptide of...

Electronic data

  • Palasz-Revised2

    Accepted author manuscript, 839 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Nesfatin-1, a unique regulatory neuropeptide of the brain

Research output: Contribution to journalLiterature review

Published
  • Artur Palasz
  • Marek Krzystanek
  • John Worthington
  • Beata Czajkowska
  • Karol Kostro
  • Ryszard Wiaderkiewicz
  • Grzegorz Bajor
Close
<mark>Journal publication date</mark>06/2012
<mark>Journal</mark>Neuropeptides
Issue number3
Volume46
Number of pages8
Pages (from-to)105-112
Publication statusPublished
Early online date5/01/12
Original languageEnglish

Abstract

Nesfatin-1, a newly discovered NUCB2-derived satiety neuropeptide is expressed in several neurons of forebrain, hindbrain, brainstem and spinal cord. This novel anorexigenic substance seems to play an important role in hypothalamic pathways regulating food intake and energy homeostasis. Nesfatin-1 immunoreactive cells are detectable in arcuate (ARC), paraventricular (PVN) and supraoptic nuclei (SON), where the peptide is colocalized with POMC/CART, NPY, oxytocin and vasopressin. The nesfatin-1 molecule interacts with a G-protein coupled receptor and its cytophysiological effect depends on inhibitory hyperpolarization of NPY/AgRP neurons in ARC and melanocortin signaling in PVN. Administration of nesfatin-1 significantly inhibits consumatory behavior and decreases weight gain in experimental animals. These recent findings suggest the evidence for nesfatin-1 involvement in other important brain functions such as reproduction, sleep, cognition and anxiety- or stress-related responses. The neuroprotective and antiapoptotic properties of nesfatin-1 were also reported. From the clinical viewpoint it should be noteworthy, that the serum concentration of nesfatin-1 may be a sensitive marker of epileptic seizures. However, the details of nesfatin-1 physiology ought to be clarified, and it may be considered suitable in the future, as a potential drug in the pharmacotherapy of obesity, especially in patients treated with antipsychotics and antidepressants. On the other hand, some putative nesfatin-1 antagonists may improve eating disorders. (C) 2011 Elsevier Ltd. All rights reserved.